The TCGA database was used to construct gene-specific survival probability panels for three types of cancers (pancreatic cancer, ovarian cancer, and breast cancer) where PARP inhibitors are predominantly used for treatment. This evidence concerns the gene PARP1 and ovarian carcinoma.